Patients
tumor, Anxiety, anxiety, non-cancer, depression, Depression
PROGRESSIVE DISEASE, TUMOR, DISEASE
As previously described (Verhaak et al. A radiation-oncologist screened for study eligibility during the first consultation visit. Eligible patients received detailed information about the study and its procedures. In the morning before GKRS, a neuropsychological assessment, consisting of 6 short neuropsychological tests and 3 self-report questionnaires, concerning anxiety and depression (Hospital Anxiety and Depression Scale; HADS (Zigmond and Snaith Follow-up tests and questionnaires took place every 3 months up to 21 months after GKRS and were combined with the usual care MRI-scans and consultations with the radiation-oncologist. The MRI-scans during follow-up were T1-weighted, contrast-enhanced images at 1.5 mm slice thickness. At time of treatment and at each follow-up, the total volume of the BM was determined. Partial response was defined as a ≥ 65% decrease in total tumor volume and no new BM. Progressive disease was defined as a ≥ 73% increase in total tumor volume or the appearance of new BM. Stable disease was defined as no partial response nor progressive disease. Only target lesions (lesions > 0.523 cmIn addition, adult Dutch non-cancer controls completed the same tests and questionnaires every 3 months up to 6 months after the first measurement (for more information refer to Verhaak et al. (